OraSure Technologies (NASDAQ:OSUR) Given New $3.00 Price Target at Stephens

OraSure Technologies (NASDAQ:OSUR) had its price objective decreased by investment analysts at Stephens from $3.50 to $3.00 in a report issued on Wednesday,Benzinga reports. The brokerage presently has an “equal weight” rating on the medical instruments supplier’s stock. Stephens’ target price suggests a potential upside of 21.95% from the stock’s previous close.

Separately, Weiss Ratings reissued a “sell (d)” rating on shares of OraSure Technologies in a research report on Wednesday, October 8th. Two analysts have rated the stock with a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Reduce” and an average target price of $3.00.

OraSure Technologies Price Performance

Shares of OSUR stock opened at $2.46 on Wednesday. The company’s fifty day moving average price is $3.03 and its two-hundred day moving average price is $2.98. The firm has a market capitalization of $176.47 million, a P/E ratio of -3.67 and a beta of 0.54. OraSure Technologies has a 12 month low of $2.30 and a 12 month high of $4.31.

OraSure Technologies (NASDAQ:OSUR) last announced its earnings results on Wednesday, November 5th. The medical instruments supplier reported ($0.13) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.16) by $0.03. The business had revenue of $27.09 million for the quarter, compared to analyst estimates of $28.96 million. OraSure Technologies had a negative return on equity of 10.81% and a negative net margin of 36.84%. OraSure Technologies has set its Q4 2025 guidance at EPS. On average, sell-side analysts anticipate that OraSure Technologies will post -0.08 EPS for the current year.

Institutional Trading of OraSure Technologies

Several hedge funds have recently made changes to their positions in the stock. Bfsg LLC grew its stake in OraSure Technologies by 8.3% during the 2nd quarter. Bfsg LLC now owns 45,680 shares of the medical instruments supplier’s stock worth $137,000 after buying an additional 3,490 shares during the last quarter. Peapod Lane Capital LLC increased its holdings in shares of OraSure Technologies by 1.1% in the 3rd quarter. Peapod Lane Capital LLC now owns 674,033 shares of the medical instruments supplier’s stock worth $2,164,000 after acquiring an additional 7,426 shares during the period. Coldstream Capital Management Inc. grew its position in OraSure Technologies by 128.2% in the 2nd quarter. Coldstream Capital Management Inc. now owns 13,308 shares of the medical instruments supplier’s stock worth $40,000 after purchasing an additional 7,477 shares during the last quarter. Murphy Pohlad Asset Management LLC increased its stake in shares of OraSure Technologies by 10.1% in the third quarter. Murphy Pohlad Asset Management LLC now owns 87,567 shares of the medical instruments supplier’s stock valued at $281,000 after purchasing an additional 8,000 shares during the period. Finally, Envestnet Asset Management Inc. raised its holdings in shares of OraSure Technologies by 32.7% during the second quarter. Envestnet Asset Management Inc. now owns 33,018 shares of the medical instruments supplier’s stock valued at $99,000 after buying an additional 8,133 shares during the last quarter. Institutional investors own 93.50% of the company’s stock.

About OraSure Technologies

OraSure Technologies, Inc, together with its subsidiaries, provides point-of-care and home diagnostic tests, specimen collection devices, and microbiome laboratory and analytical services in the United States, Europe, and internationally. The company’s products include InteliSwab COVID-19 rapid test, InteliSwab COVID-19 rapid test pro, InteliSwab COVID-19 rapid test rx, OraQuick Rapid HIV test, OraQuick In-Home HIV test, OraQuick HIV self-test, OraQuick HCV rapid antibody test, OraQuick Ebola rapid antigen test, OraSure oral fluid collection device used in conjunction with screening and confirmatory tests for HIV-1 antibodies; Intercept drug testing systems; immunoassay tests and reagents; and Q.E.D.